Cargando…

Closantel; a veterinary drug with potential severe morbidity in humans

BACKGROUND: Closantel is a halogenated salicylanilide with a potent anti parasitic activity. It is widely used in management of parasitic infestation in animals, but is contraindicated in humans. CASE PRESENTATION: A 34-year-old man with depression was referred to our center with progressive loss of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabatabaei, Seyed Ali, Soleimani, Mohammad, Mansouri, Mohammad Reza, Mirshahi, Ahmad, Inanlou, Bahman, Abrishami, Mojtaba, Pakrah, Ahmad Reza, Masarat, Hamideh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129234/
https://www.ncbi.nlm.nih.gov/pubmed/27899086
http://dx.doi.org/10.1186/s12886-016-0387-x
_version_ 1782470551927783424
author Tabatabaei, Seyed Ali
Soleimani, Mohammad
Mansouri, Mohammad Reza
Mirshahi, Ahmad
Inanlou, Bahman
Abrishami, Mojtaba
Pakrah, Ahmad Reza
Masarat, Hamideh
author_facet Tabatabaei, Seyed Ali
Soleimani, Mohammad
Mansouri, Mohammad Reza
Mirshahi, Ahmad
Inanlou, Bahman
Abrishami, Mojtaba
Pakrah, Ahmad Reza
Masarat, Hamideh
author_sort Tabatabaei, Seyed Ali
collection PubMed
description BACKGROUND: Closantel is a halogenated salicylanilide with a potent anti parasitic activity. It is widely used in management of parasitic infestation in animals, but is contraindicated in humans. CASE PRESENTATION: A 34-year-old man with depression was referred to our center with progressive loss of vision in both eyes 10 days after unintentional ingestion of three 500 mg tablets of Closantel. On fundus examination, left optic disc margin was blurred. His bilateral visual acuity was no light perception (NLP) despite prescribed IV erythropoietin injections 20,000 units daily for 3 days and 1gr intravenous methylprednisolone acetate for 3 days followed by 1 mg/kg oral prednisolone. On macular optical coherence tomography (OCT), a disruption in outer retina was observed. Electroretinogram and visual evoked potential tests showed visual pathway involvement. CONCLUSIONS: Destruction of neurosensory retina and visual pathways after accidental Closantel use is related to severe visual loss. This case alerts us about the destructive effect of this drug on humans even in low dosage which necessitates preventive efforts to reduce the chance of this morbid side effect.
format Online
Article
Text
id pubmed-5129234
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51292342016-12-12 Closantel; a veterinary drug with potential severe morbidity in humans Tabatabaei, Seyed Ali Soleimani, Mohammad Mansouri, Mohammad Reza Mirshahi, Ahmad Inanlou, Bahman Abrishami, Mojtaba Pakrah, Ahmad Reza Masarat, Hamideh BMC Ophthalmol Case Report BACKGROUND: Closantel is a halogenated salicylanilide with a potent anti parasitic activity. It is widely used in management of parasitic infestation in animals, but is contraindicated in humans. CASE PRESENTATION: A 34-year-old man with depression was referred to our center with progressive loss of vision in both eyes 10 days after unintentional ingestion of three 500 mg tablets of Closantel. On fundus examination, left optic disc margin was blurred. His bilateral visual acuity was no light perception (NLP) despite prescribed IV erythropoietin injections 20,000 units daily for 3 days and 1gr intravenous methylprednisolone acetate for 3 days followed by 1 mg/kg oral prednisolone. On macular optical coherence tomography (OCT), a disruption in outer retina was observed. Electroretinogram and visual evoked potential tests showed visual pathway involvement. CONCLUSIONS: Destruction of neurosensory retina and visual pathways after accidental Closantel use is related to severe visual loss. This case alerts us about the destructive effect of this drug on humans even in low dosage which necessitates preventive efforts to reduce the chance of this morbid side effect. BioMed Central 2016-11-29 /pmc/articles/PMC5129234/ /pubmed/27899086 http://dx.doi.org/10.1186/s12886-016-0387-x Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Tabatabaei, Seyed Ali
Soleimani, Mohammad
Mansouri, Mohammad Reza
Mirshahi, Ahmad
Inanlou, Bahman
Abrishami, Mojtaba
Pakrah, Ahmad Reza
Masarat, Hamideh
Closantel; a veterinary drug with potential severe morbidity in humans
title Closantel; a veterinary drug with potential severe morbidity in humans
title_full Closantel; a veterinary drug with potential severe morbidity in humans
title_fullStr Closantel; a veterinary drug with potential severe morbidity in humans
title_full_unstemmed Closantel; a veterinary drug with potential severe morbidity in humans
title_short Closantel; a veterinary drug with potential severe morbidity in humans
title_sort closantel; a veterinary drug with potential severe morbidity in humans
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129234/
https://www.ncbi.nlm.nih.gov/pubmed/27899086
http://dx.doi.org/10.1186/s12886-016-0387-x
work_keys_str_mv AT tabatabaeiseyedali closantelaveterinarydrugwithpotentialseveremorbidityinhumans
AT soleimanimohammad closantelaveterinarydrugwithpotentialseveremorbidityinhumans
AT mansourimohammadreza closantelaveterinarydrugwithpotentialseveremorbidityinhumans
AT mirshahiahmad closantelaveterinarydrugwithpotentialseveremorbidityinhumans
AT inanloubahman closantelaveterinarydrugwithpotentialseveremorbidityinhumans
AT abrishamimojtaba closantelaveterinarydrugwithpotentialseveremorbidityinhumans
AT pakrahahmadreza closantelaveterinarydrugwithpotentialseveremorbidityinhumans
AT masarathamideh closantelaveterinarydrugwithpotentialseveremorbidityinhumans